Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine
This article, published by The New England Journal of Medicine, details the findings of a single-center study in the United Kingdom to test the monovalent influenza A/California/2009 (H1N1) surface-antigen vaccine, in both MF59-adjuvanted and nonadjuvanted forms. Study findings suggest that MF59-adjuvanted vaccine generates antibody responses likely to be associated with protection after the administration of a single dose to adults 18 to 50 years of age. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author(s): Clark TW, Pareek M, Hoschler K, et al.
Visit web page (English)
(Located at content.nejm.org)
Citation: Clark TW, Pareek M, Hoschler K, et al. Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine. New England Journal of Medicine. 2009;361(25):2424-2435.